AUSTEDO® (deutetrabenazine) tablets and AUSTEDO XR® (deutetrabenazine) extended-release tablets Demonstrate Positive Real-world Impact, with Patients Reporting Improvement in ...

In a new cohort of 27 adults from the IMPACT-TD Registry, up to 77% of participants reported improvements in aspects of their lives impacted by ...
FierceBiotech

NUCYNTA® ER (Tapentadol Extended-Release Tablets) Receives FDA Approval for the Management of Moderate to Severe Chronic Pain

RARITAN, N.J., Aug. 26, 2011 /PRNewswire via COMTEX/ -- Janssen Pharmaceuticals, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved NUCYNTA® ER, an oral analgesic taken ...
Nasdaq

ANI Announces Launch of Paliperidone Extended-Release Tablets

BAUDETTE, Minn., Jan. 14, 2020 /PRNewswire/ -- ANI Pharmaceuticals, Inc. ("ANI") (Nasdaq: ANIP) today announced the launch of Paliperidone Extended-Release Tablets, 1.5 mg, 3 mg, 6 mg and 9 mg. The ...
FiercePharma

FDA Approves NUCYNTA® ER (tapentadol) Extended-Release Oral Tablets for the Management of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy

FDA Approves NUCYNTA ® ER (tapentadol) Extended-Release Oral Tablets for the Management of Neuropathic Pain Associated with Diabetic Peripheral Neuropathy Clinical Trial Data Demonstrate Efficacy and ...
FiercePharma

KOMBIGLYZE™ XR (Saxagliptin and Metformin HCl Extended-Release) Tablets Approved in the U.S. for the Treatment of Type 2 D

PRINCETON, N.J. & LONDON--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and AstraZeneca (NYSE: AZN) today announced that the U.S. Food and Drug Administration (FDA) approved KOMBIGLYZE ™ ...
Wane

Patients Taking AUSTEDO XR® (deutetrabenazine) extended-release tablets Reported Symptom Improvement and High Satisfaction

Of the 209 patients with tardive dyskinesia (TD) that were surveyed, >94% reported movement improvement once treated with AUSTEDO XR ® (deutetrabenazine) extended-release tablets Patients reported ...
Nasdaq

FDA Approves XELJANZ® XR (tofacitinib) Extended-Release Tablets for the Treatment of Ulcerative Colitis

Pfizer Inc. (NYSE:PFE) announced today that the U.S. Food and Drug Administration (FDA) has approved XELJANZ® XR (tofacitinib) extended-release 11 mg and 22 mg tablets for the once-daily treatment of ...
Monthly Prescribing Reference

Morphine Sulfate Extended-Release Tablets Recalled Due to Incorrect Labeling

Patients prescribed the 30mg dose who receive the 60mg dose may potentially be at risk for overdose and death. Bryant Ranch Prepack Inc. has voluntarily recalled 1 lot of Morphine Sulfate 30mg ...
Yahoo Finance

Kye Pharmaceuticals Announces the Approval of DYANAVEL® XR (amphetamine extended-release) Tablets and Oral Suspension for the Treatment of Adults and Children With ADHD

MISSISSAUGA, ON, Aug. 5, 2025 /CNW/ - Kye Pharmaceuticals Inc. ("Kye"), a leading Canadian-based commercial-stage specialty pharmaceutical company focused on licensing and commercializing innovative ...
WRIC

Extended-release morphine tablets recalled

WASHINGTON, D.C. (WRIC) — Virginians who take morphine to manage pain are asked to check their bottles after a voluntary recall. Bryant Ranch Prepack, Inc. is voluntarily recalling one lot of 30mg ...
Healio

FDA approves Xeljanz extended release tablets for ulcerative colitis

The FDA on Thursday approved Xeljanz extended release 11 mg and 22 mg tablets for the once daily treatment of adults with moderately to severely active ulcerative colitis, following an inadequate ...